This study developed a Gly/Ser/Thr pathway-based prognostic model for EC, based on the expression of MTHFD2, RPS6KA1, and CDKN2A as novel biomarkers. The resulting patient stratification framework holds significant clinical potential for guiding precise and personalized management of EC.
Ye et al. (Wed,) studied this question.